RNA Interference Mediated Survivin Gene Silence Can Inhibit The Growth Of Xenografed Prostate Cancer In Nude Mice

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Genetics;  Clinical Trials / Drug Trials
Article Date: 09 Jun 2008 - 10:00 PDT

email to a friend   printer friendly   opinions  

ORLANDO, FL (UroToday.com) - Researchers from China reported on the RNA interference of surviving gene expression with relation to effects on cell proliferation and apoptosis in hormone-refractory prostate cancer PC-3 cell lines and prostate cancer xenografts.

Two small hairpain RNA targeted to survivin mRNA were constructed and synthesized, then inserted into the adenovirus vector, named rAd-T-sur. rAd-T-sur was transfected into PC-3 cells and cell growth was studied. Survivin protein expression and apoptosis in PC-3 cell were analyzed after transfection for 48 hours. PC3 xenografts of prostate cancer were implanted in BALB/C nude mice subcutaneously and then injected with rAd-T-sur directly.

After rAd-T-sur was transfected, PC-3 cell proliferation was inhibited. Forty-eight hours after transfection, the expression of survivin protein was 2.33%±0.63%, 53.20%±5.62% and 56.63%±4.57% in the experimental group, negative control group and the blank group, respectively and the apoptosis rate increased. Xenograft volume was inhibited 59.5% as compared with the control group after injection with rAd-T-sur for one month. Survivin gene expression was reduced and cell apoptosis was observed in the xenografts.

RNA interference mediated survivin gene silencing can effectively inhibited the cell proliferation and induce apoptosis of prostate cancer in vivo and in vitro. This method may be a new approach for the treatment of prostate cancer.

Presented by Dong Rong Yang, MD, Yu Xi Shan, MD, Peng Gao, MD, and Guan Tian Yang, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations